Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)
Scope of the Report
The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.
The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.
The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.
Company Coverage
Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.
In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. Actelion develop the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.
Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.
The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.
The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.
The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.
Company Coverage
- Actelion Limited
- United Therapeutics Limited
- SteadyMed Limited
- Endothelin Receptor Antagonists (ERA)
- PDE 5 Inhibitors
- Prostacyclins
- sGC Stimulator
Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.
In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. Actelion develop the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.
Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.
1. EXECUTIVE SUMMARY
2. PULMONARY ARTERIAL HYPERTENSION (PAH): AN INTRODUCTION
2.1 Definition of PAH
2.2 Classification of PAH
2.3 Causes of PAH
2.4 Who gets PAH?
2.5 How Serious is PAH?
2.6 Symptoms of PAH
2.7 Diagnosis of PAH
2.8 Treatment of PAH
2.8.1 Medications
2.8.2 Surgery
2.8.3 Lifestyle Changes
2.9 How does it affect?
3. GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET: AN ANALYSIS
3.1 Global PAH Market – Size and Growth: Actual & Forecast
3.2 Global PAH Market by Drug Mechanism: Actual & Forecast
3.2.1 Global Endothelin Receptor Antagonists (ERA) Market Size: Actual & Forecast
3.2.2 Global PDE 5 Inhibitors Market Size: Actual & Forecast
3.2.3 Global Prostacyclins Market Size: Actual & Forecast
3.2.4 Global sGC Stimulator Market Size: Actual & Forecast
3.3 Global PAH Drug Sales by Dosage Forms
3.4 Global Parenteral Prostacyclins Drug Sales
3.5 Global Inhaled Prostacyclins Drug Sales
3.6 Global Oral PAH Drugs Sales (ERAs, PDE5s, Prostacyclins)
4. GLOBAL PAH MARKET SHARE: AN ANALYSIS
4.1 Global PAH Drug Classes Market Share by Value
4.2 Global PAH Drug Classes Market Share by Prescription Volumes
4.3 Global PAH Market Share by Dosages Forms
4.4 Global PAH Market Share by Drug Sales
4.5 Global PAH Market Share by Regions
5. PATCH PUMP TECHNOLOGY MARKET: AN ANALYSIS
5.1 Trevyent Patch Pump
5.2 Remodulin
5.3 Trevyent vs. Remodulin
6. MARKET DYNAMICS:GLOBAL PAH MARKET
6.1 Growth Drivers
6.1.1 High Unmet Medical Needs
6.1.2 Launch of New PAH Drugs
6.1.3 Increased Awareness
6.1.4 No Alternative Affordable Treatment
6.2 Challenges
6.2.1 Heightened Competition
6.2.2 Very Low Volumes of Patients and Challenges in Diagnosis of PAH
6.3 Market Trends
6.3.1 Newer Therapies Replacing the Old Ones
6.3.2 Increasing Interest of Big Pharma
7. COMPETITIVE LANDSCAPE:GLOBAL PAH MARKET
8. COMPANY PROFILES:GLOBAL PAH MARKET
8.1 Actelion Ltd.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 United Therapeutics Ltd.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 SteadyMed Ltd.
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
2. PULMONARY ARTERIAL HYPERTENSION (PAH): AN INTRODUCTION
2.1 Definition of PAH
2.2 Classification of PAH
2.3 Causes of PAH
2.4 Who gets PAH?
2.5 How Serious is PAH?
2.6 Symptoms of PAH
2.7 Diagnosis of PAH
2.8 Treatment of PAH
2.8.1 Medications
2.8.2 Surgery
2.8.3 Lifestyle Changes
2.9 How does it affect?
3. GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET: AN ANALYSIS
3.1 Global PAH Market – Size and Growth: Actual & Forecast
3.2 Global PAH Market by Drug Mechanism: Actual & Forecast
3.2.1 Global Endothelin Receptor Antagonists (ERA) Market Size: Actual & Forecast
3.2.2 Global PDE 5 Inhibitors Market Size: Actual & Forecast
3.2.3 Global Prostacyclins Market Size: Actual & Forecast
3.2.4 Global sGC Stimulator Market Size: Actual & Forecast
3.3 Global PAH Drug Sales by Dosage Forms
3.4 Global Parenteral Prostacyclins Drug Sales
3.5 Global Inhaled Prostacyclins Drug Sales
3.6 Global Oral PAH Drugs Sales (ERAs, PDE5s, Prostacyclins)
4. GLOBAL PAH MARKET SHARE: AN ANALYSIS
4.1 Global PAH Drug Classes Market Share by Value
4.2 Global PAH Drug Classes Market Share by Prescription Volumes
4.3 Global PAH Market Share by Dosages Forms
4.4 Global PAH Market Share by Drug Sales
4.5 Global PAH Market Share by Regions
5. PATCH PUMP TECHNOLOGY MARKET: AN ANALYSIS
5.1 Trevyent Patch Pump
5.2 Remodulin
5.3 Trevyent vs. Remodulin
6. MARKET DYNAMICS:GLOBAL PAH MARKET
6.1 Growth Drivers
6.1.1 High Unmet Medical Needs
6.1.2 Launch of New PAH Drugs
6.1.3 Increased Awareness
6.1.4 No Alternative Affordable Treatment
6.2 Challenges
6.2.1 Heightened Competition
6.2.2 Very Low Volumes of Patients and Challenges in Diagnosis of PAH
6.3 Market Trends
6.3.1 Newer Therapies Replacing the Old Ones
6.3.2 Increasing Interest of Big Pharma
7. COMPETITIVE LANDSCAPE:GLOBAL PAH MARKET
8. COMPANY PROFILES:GLOBAL PAH MARKET
8.1 Actelion Ltd.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 United Therapeutics Ltd.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 SteadyMed Ltd.
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
LIST OF FIGURES AND TABLES
Figure 1: Pulmonary Circulation of a PAH Patient vs. an Unaffected Person
Figure 2: PAH Treatment Schedule by Disease Severity
Figure 3: PAH Diagnoses
Figure 4: PAH Associated with Other Diseases (APAH)
Figure 5: Global PAH Market by Value; 2010-2014 (US$ Billion)
Figure 6: Global PAH Market by Value Forecast; 2015-2019 (US$ Billion)
Figure 7: Global Endothelin Receptor Antagonists (ERA) Market by Value; 2010-2014 (US$ Million)
Figure 8: Global Endothelin Receptor Antagonists (ERA) Market by Value Forecast; 2015-2019 (US$ Million)
Figure 9: Global PDE 5 Inhibitors Market by Value; 2010-2014 (US$ Million)
Figure 10: Global PDE 5 Inhibitors Market by Value Forecast; 2015-2019 (US$ Million)
Figure 11: Global Prostacyclins Market by Value; 2010-2014 (US$ Million)
Figure 12: Global Prostacyclins Market by Value Forecast; 2015-2019 (US$ Million)
Figure 13: Global PAH Drug Sales by Dosage Forms; 2014 (US$ Million)
Figure 14: Global Parenteral Prostacyclins Drug Sales Breakdown; 2014 (US$ Million)
Figure 15: Global Inhaled Prostacyclins Drug Sales Breakdown; 2014 (US$ Million)
Figure 16: Global Oral PAH Drugs Sales Breakdown; 2014 (US$ Million)
Figure 17: Global PAH Drug Classes Market Share by Value; 2013
Figure 18: Global PAH Drug Classes Market Share by Prescription Volumes; 2013
Figure 19: Global PAH Market Share by Dosages Forms; 2014
Figure 20: Global PAH Market Share by Drug Sales; 2014
Figure 21: Global PAH Market Share by Regions; 2014
Figure 22: Trevyent Patch Pump Technology
Figure 23: Remodulin Net Sales; 2013-2014 (US$ Million)
Figure 24: Trevyent Net Sales in US; 2017E-2020E (US$ Million)
Figure 25: Market Opportunity for Trevyent
Figure 26: Number of Patients Diagnosed & Treated in US; 2014-2019E
Figure 27: Actelion Net Sales; 2010-2014 (US$ Million)
Figure 28: Actelion PAH Product Sales; 2014 (US$ Million)
Figure 29: United Therapeutics Limited Net Sales; 2010-2014 (US$ Million)
Table 1: PAH Survival Rates, 2014
Table 2: Cost of PAH Treatment
Table 3: Trevyent vs. Remodulin
Table 4: Competitive Landscape of PAH Market Key Players, 2014
Table 5: PAH Endothelin Antagonist Drug Comparison
Table 6: PAH PDE5 Inhibitor Drug Comparison
Table 7: PAH Prostacyclin Drug Comparison
Table 8: PAH sCG Stimulator Drug
Table 9: Actelion Development Pipeline
Table 10: Financial Overview of SteadyMed; 2012-2014
Figure 1: Pulmonary Circulation of a PAH Patient vs. an Unaffected Person
Figure 2: PAH Treatment Schedule by Disease Severity
Figure 3: PAH Diagnoses
Figure 4: PAH Associated with Other Diseases (APAH)
Figure 5: Global PAH Market by Value; 2010-2014 (US$ Billion)
Figure 6: Global PAH Market by Value Forecast; 2015-2019 (US$ Billion)
Figure 7: Global Endothelin Receptor Antagonists (ERA) Market by Value; 2010-2014 (US$ Million)
Figure 8: Global Endothelin Receptor Antagonists (ERA) Market by Value Forecast; 2015-2019 (US$ Million)
Figure 9: Global PDE 5 Inhibitors Market by Value; 2010-2014 (US$ Million)
Figure 10: Global PDE 5 Inhibitors Market by Value Forecast; 2015-2019 (US$ Million)
Figure 11: Global Prostacyclins Market by Value; 2010-2014 (US$ Million)
Figure 12: Global Prostacyclins Market by Value Forecast; 2015-2019 (US$ Million)
Figure 13: Global PAH Drug Sales by Dosage Forms; 2014 (US$ Million)
Figure 14: Global Parenteral Prostacyclins Drug Sales Breakdown; 2014 (US$ Million)
Figure 15: Global Inhaled Prostacyclins Drug Sales Breakdown; 2014 (US$ Million)
Figure 16: Global Oral PAH Drugs Sales Breakdown; 2014 (US$ Million)
Figure 17: Global PAH Drug Classes Market Share by Value; 2013
Figure 18: Global PAH Drug Classes Market Share by Prescription Volumes; 2013
Figure 19: Global PAH Market Share by Dosages Forms; 2014
Figure 20: Global PAH Market Share by Drug Sales; 2014
Figure 21: Global PAH Market Share by Regions; 2014
Figure 22: Trevyent Patch Pump Technology
Figure 23: Remodulin Net Sales; 2013-2014 (US$ Million)
Figure 24: Trevyent Net Sales in US; 2017E-2020E (US$ Million)
Figure 25: Market Opportunity for Trevyent
Figure 26: Number of Patients Diagnosed & Treated in US; 2014-2019E
Figure 27: Actelion Net Sales; 2010-2014 (US$ Million)
Figure 28: Actelion PAH Product Sales; 2014 (US$ Million)
Figure 29: United Therapeutics Limited Net Sales; 2010-2014 (US$ Million)
Table 1: PAH Survival Rates, 2014
Table 2: Cost of PAH Treatment
Table 3: Trevyent vs. Remodulin
Table 4: Competitive Landscape of PAH Market Key Players, 2014
Table 5: PAH Endothelin Antagonist Drug Comparison
Table 6: PAH PDE5 Inhibitor Drug Comparison
Table 7: PAH Prostacyclin Drug Comparison
Table 8: PAH sCG Stimulator Drug
Table 9: Actelion Development Pipeline
Table 10: Financial Overview of SteadyMed; 2012-2014
